日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Synergistic effect of MDM2 inhibitors and radiotherapy in endometrial cancer

MDM2抑制剂与放射疗法在子宫内膜癌中的协同作用

Vargas, Roberto; Petty, Aaron; Lindner, Daniel J; Parker, Yvonne; Yard, Brian; Durmaz, Arda; Lin-Rahardja, Kristi; Reizes, Ofer; Debernardo, Robert; Scott, Jacob

Implications of GLP-1 Agonists on Office-Based Sedation and General Anesthesia for Dentistry

GLP-1受体激动剂对牙科诊室镇静和全身麻醉的影响

McKenzie, Craig; DeBernardo, Alexander; Schwartz, Paul

Single-Agent Total Intravenous Anesthesia With Remimazolam for an Elderly Man Undergoing Ambulatory Oral Surgery: A Case Report

老年男性行门诊口腔手术,采用瑞马唑仑单药全静脉麻醉:病例报告

DeBernardo, Alexander J; Aziz, Huda A; Douglas, Kira; Cuddy, Michael A; Sosovicka, Mark; Saxen, Mark; Giovannitti, Joseph A Jr; McKenzie, Craig; Herlich, Andrew

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer

卡铂、紫杉醇和帕博利珠单抗联合化疗,随后进行帕博利珠单抗维持治疗,用于不完全切除的上皮性卵巢癌的一线治疗。

Uyar, Denise; Michener, Chad M; Bishop, Erin; Hopp, Elizabeth; Simpson, Pippa; Zhang, Liyun; Rader, Janet S; Rose, Peter G; Mahdi, Haider S; Debernardo, Robert; Christian, Qiana; Bradley, William

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283

达沙替尼治疗复发性卵巢、输卵管、腹膜或子宫内膜透明细胞癌的 II 期研究:NRG 肿瘤/妇科肿瘤组 0283 研究

O'Cearbhaill, Roisin E; Miller, Austin; Soslow, Robert A; Lankes, Heather A; DeLair, Deborah; Segura, Sheila; Chavan, Shweta; Zamarin, Dmitriy; DeBernardo, Robert; Moore, Kathleen; Moroney, John; Shahin, Mark; Thaker, Premal H; Wahner-Hendrickson, Andrea E; Aghajanian, Carol

Surgical management of spontaneous bowel perforation and fascial dehiscence in a patient on bevacizumab and pembrolizumab in the setting of active Clostridium difficile infection

在接受贝伐珠单抗和帕博利珠单抗治疗且合并艰难梭菌感染的患者中,发生自发性肠穿孔和筋膜裂开的手术治疗

Mubashir, Mujtaba; Tang, Brian; DeBernardo, Robert L; Feng, Xiaoxi

Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259)

WRITE症状干预对复发性卵巢癌患者症状和生活质量的影响:NRG肿瘤/GOG研究(GOG-0259)

Donovan, Heidi S; Sereika, Susan M; Wenzel, Lari B; Edwards, Robert P; Knapp, Judith E; Hughes, Susan H; Roberge, Mary C; Thomas, Teresa H; Klein, Sara Jo; Spring, Michael B; Nolte, Susan; Landrum, Lisa M; Casey, A Catherine; Mutch, David G; DeBernardo, Robert L; Muller, Carolyn Y; Sullivan, Stephanie A; Ward, Sandra E

Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer

评估卵巢癌女性接受腹腔热灌注化疗的交通距离

Chambers, Laura M; Yao, Meng; Morton, Molly; Gruner, Morgan; Chichura, Anna; Costales, Anthony B; Horowitz, Max; Rose, Peter G; Michener, Chad M; Debernardo, Robert

Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors

LCK抑制剂预处理可增强顺铂耐药性子宫内膜样卵巢肿瘤的化疗敏感性

Katie K Crean-Tate,Chad Braley,Goutam Dey,Emily Esakov,Caner Saygin,Alexandria Trestan,Daniel J Silver,Soumya M Turaga,Elizabeth V Connor,Robert DeBernardo,Chad M Michener,Peter G Rose,Justin Lathia,Ofer Reizes

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma

乐伐替尼联合帕博利珠单抗治疗晚期或复发性子宫癌肉瘤患者

Hunt, Jonathan T; Chambers, Laura M; Yao, Meng; Joehlin-Price, Amy; Debernardo, Robert; Rose, Peter G